Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 SEK | -3.15% | -11.60% | -9.71% |
Apr. 29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
Apr. 29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Sales 2022 | 1.14M 106K | Sales 2023 | 1.58M 145K | Capitalization | 80.25M 7.4M |
---|---|---|---|---|---|
Net income 2022 | -168M -15.49M | Net income 2023 | -309M -28.49M | EV / Sales 2022 | 460 x |
Net cash position 2022 | 68.47M 6.31M | Net cash position 2023 | 72.5M 6.69M | EV / Sales 2023 | 4.92 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-0.22
x | Employees | 11 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.11% |
Latest transcript on Immunovia AB
1 day | -2.18% | ||
1 week | -9.39% | ||
Current month | -19.21% | ||
1 month | -9.39% | ||
3 months | -1.20% | ||
6 months | -43.64% | ||
Current year | -7.45% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 1.6 | -3.15% | 239 824 |
24-05-10 | 1.652 | -4.73% | 387,401 |
24-05-08 | 1.734 | -3.88% | 99,225 |
24-05-07 | 1.804 | -0.33% | 144,300 |
24-05-06 | 1.81 | -2.79% | 182,387 |
Delayed Quote Nasdaq Stockholm, May 13, 2024 at 08:26 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-7.45% | 6.9M | |
-16.99% | 18.62B | |
-42.18% | 2.85B | |
+22.02% | 1.94B | |
+0.39% | 1.68B | |
+26.10% | 1.26B | |
-10.70% | 1.03B | |
-18.27% | 938M | |
-0.44% | 783M | |
-25.07% | 628M |
- Stock Market
- Equities
- IMMNOV Stock